Balance Sheet

Accounts Payables Accumulated Expenses Assets Cash & Current Investments Cash & Equivalents Common Equity Convertible Debt Current Assets Current Leases Finished Goods Goodwill Goodwill & Intangibles Intangibles Inventory Liabilities and Shareholders Equity Liabilities from Discontinued Operations Liabilities from Discontinued Operations Long-Term Investments Non-Current Assets Non-Current Debt Non-Current Deferred Tax Liability Non-Current Deferred Tax Liability Operating Leases Other Accumulated Expenses Other Non-Current Assets Other Non-Current Liabilities Payables Preferred Stock Liabilities Prepaid Assets Property, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw Materials Receivables Receivables - Net Receivables - Other Retained Earnings Shareholder's Equity Shares Outstanding Short term Debt Short-term Investments Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Treasury Shares Work In Process

Cash Flow Statement

Daily Values

Growth Metrics

Others

Soleno Therapeutics (SLNO) Finished Goods (2025)

Soleno Therapeutics (SLNO) has disclosed Finished Goods for 1 consecutive years, with $6.0 million as the latest value for Q4 2025.

For Q4 2025, Finished Goods changed N/A year-over-year to $6.0 million; the TTM value through Dec 2025 reached $6.0 million, changed N/A, while the annual FY2025 figure was $6.0 million, N/A changed from the prior year.
Finished Goods hit $6.0 million in Q4 2025 for Soleno Therapeutics, up from $525000.0 in the prior quarter.
Across five years, Finished Goods topped out at $6.0 million in Q4 2025 and bottomed at $262000.0 in Q2 2025.